We also think that the expansion of both CD4+ and CD8+ Tregs in vivo in SLE will have more beneficial effects than that of each subset alone because of the protective activity of CD8+ Tregs in the disease (15). The gene discussed is CD4; the disease is systemic lupus erythematosus.